# Brian Abaluck

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/brian-abaluck/

## Facts

| Field | Value |
| --- | --- |
| Citations | 203 |
| Field | Sleep and Wakefulness Research |
| h-index | 4 |
| i10-index | 3 |
| Last Known Institution | Avanir Pharmaceuticals (United States) |
| OpenAlex ID | https://openalex.org/A5047269963 |
| Works | 22 |

## Researcher papers

- [The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial](https://scholariq.org/papers/the-combination-of-aroxybutynin-and-atomoxetine-in-the-treatment-of-obstructive/)
- [NightBalance Sleep Position Treatment Device Versus Auto-Adjusting Positive Airway Pressure for Treatment of Positional Obstructive Sleep Apnea](https://scholariq.org/papers/nightbalance-sleep-position-treatment-device-versus-auto-adjusting-positive/)
- [Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA](https://scholariq.org/papers/combination-of-atomoxetine-with-the-novel-antimuscarinic-aroxybutynin-improves/)
- [RESTORE: Once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates](https://scholariq.org/papers/restore-once-nightly-oxybate-dosing-preference-and-nocturnal-experience-with/)
- [Sleepiness in healthcare workers](https://scholariq.org/papers/sleepiness-in-healthcare-workers/)
- [0538 Mariposa: Oral Therapy AD109 Improves Objective & Patient Reported Outcomes In OSA. Randomized, Placebo Controlled Clinical Trial](https://scholariq.org/papers/0538-mariposa-oral-therapy-ad109-improves-objective-and-amp-patient-reported/)
- [0589 Dose Titration of Once-Nightly Sodium Oxybate: Analysis of Interim Data From RESTORE](https://scholariq.org/papers/0589-dose-titration-of-once-nightly-sodium-oxybate-analysis-of-interim-data-from/)
- [0732 Drug Class Utilization and Age-Related Trends in Narcolepsy and Idiopathic Hypersomnia: A Claims Database Analysis](https://scholariq.org/papers/0732-drug-class-utilization-and-age-related-trends-in-narcolepsy-and-idiopathic/)
- [0411 Once-Nightly Sodium Oxybate Dose Titration and Tolerability: Interim Data From RESTORE](https://scholariq.org/papers/0411-once-nightly-sodium-oxybate-dose-titration-and-tolerability-interim-data/)
- [DOSE TITRATION AND TOLERABILITY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM DATA FROM RESTORE](https://scholariq.org/papers/dose-titration-and-tolerability-of-once-nightly-sodium-oxybate-interim-data-from/)
- [RELATIVE PREVALENCE OF IDIOPATHIC HYPERSOMNIA, NARCOLEPSY TYPE 1, AND NARCOLEPSY TYPE 2: A CLAIMS DATABASE ANALYSIS](https://scholariq.org/papers/relative-prevalence-of-idiopathic-hypersomnia-narcolepsy-type-1-and-narcolepsy/)

## Researcher topics

- [Sleep and Wakefulness Research](https://scholariq.org/topics/sleep-and-wakefulness-research/)
- [Sleep and related disorders](https://scholariq.org/topics/sleep-and-related-disorders/)
- [Neuroscience of respiration and sleep](https://scholariq.org/topics/neuroscience-of-respiration-and-sleep/)
- [Obstructive Sleep Apnea Research](https://scholariq.org/topics/obstructive-sleep-apnea-research/)
- [Psychosomatic Disorders and Their Treatments](https://scholariq.org/topics/psychosomatic-disorders-and-their-treatments/)

## Researcher university

- [Avanir Pharmaceuticals (United States)](https://scholariq.org/institutions/avanir-pharmaceuticals-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.